Chemomab Therapeutics (CMMB) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Chemomab Therapeutics Ltd (CMMB) Prix de l'Action, Cotation, Actualités et Historique

CMMBNASDAQ

Trade with Public

Trade with Public

$1.17

-0.095-7.51%

Dern. MÀJ: Oct 19, 5:31 PM

$1.21

-0.0564-4.46%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

$1.25

Clôture

$1.17

Volume / Moy.

36.62K / 103.44K

Fourchette Journalière

$1.17 - $1.26

Plage 52 Sem.

1.05 - 3.50

Capitalisation Boursière

$8.86M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

29

Intérêt à Découvert

0.15%

Jours pour Couvrir

1

Actualités Récentes de Chemomab Therapeutics Ltd

Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis biomarkers, and cholestasis markers.

Vandana Singh

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Avi Kapoor

Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise

Chemomab Therapeutics reports successful Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis, showing safety and efficacy. Key findings include significant improvements in liver stiffness and pruritis, with a favorable safety profile.

Vandana Singh

What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary sclerosing cholangitis. Topline data readout expected by mid-2024.

Vandana Singh

Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdings announced an agreement pursuant to which a wholly-owned subsidiary of Sekisui House will acquire MDC in an all-cash deal with an equity value of $4.9 billion.

Avi Kapoor

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-8.73M

Flux de Trésorerie d'Investissement (TTM)

3.22M

Flux de Trésorerie de Financement (TTM)

5.91M

Flux de Trésorerie Libre (TTM)

-8.74M

Dépenses en Capital (TTM)

-

Variation Nette de la Trésorerie (TTM)

403.00K

Évaluation et prévisions des analystes

4.2

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

-$1.10M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

-

Ratio P/B (TTM)

1.07

Rendement des Bénéfices % (TTM)

-75.89%

Rendement des Bénéfices % (FWD)

-

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$1.19

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-

Trésorerie Totale

$6.00M

Dette sur Capitaux Propres

-

Émission de Dette (TTM)

-

Remboursement de la Dette (TTM)

-